Van Eck Associates Corp Abb Vie Inc. Transaction History

Van Eck Associates Corp

$64.4 Billion
Q1 2024

A detailed history of Van Eck Associates Corp transactions in Abb Vie Inc. stock. As of the latest transaction made, Van Eck Associates Corp holds 217,297 shares of ABBV stock, worth $37.3 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

217,297

Previous 168,013 29.33%

Holding current value

$37.3 Million

Previous $26 Million 51.97%

% of portfolio

0.06%

Previous 0.05%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 30, 2024	BUY	$159.82 - $182.1 $7.88 Million - $8.97 Million	49,284 Added 29.33%	217,297 $39.6 Million
Q4 2023 Feb 05, 2024	SELL	$137.6 - $154.97 $122,876 - $138,388	-893 Reduced 0.53%	168,013 $26 Million
Q3 2023 Nov 08, 2023	BUY	$133.59 - $154.65 $1.34 Million - $1.55 Million	10,015 Added 6.3%	168,906 $25.2 Million
Q2 2023 Aug 03, 2023	BUY	$132.51 - $164.9 $203,667 - $253,451	1,537 Added 0.98%	158,891 $21.4 Million
Q1 2023 May 03, 2023	SELL	$144.61 - $166.54 $9.4 Million - $10.8 Million	-65,003 Reduced 29.23%	157,354 $25.1 Million

Q4 2022 Feb 08, 2023	SELL	$138.31 - $165.87 $10.2 Million - $12.2 Million	-73,685 Reduced 24.89%	222,357 $35.9 Million
Q3 2022 Oct 27, 2022	BUY	$134.21 - $153.93 $2.7 Million - $3.1 Million	20,135 Added 7.3%	296,042 $39.7 Million
Q2 2022 Aug 03, 2022	BUY	$137.62 - $174.96 $6.29 Million - $7.99 Million	45,678 Added 19.84%	275,907 $42.3 Million
Q1 2022 May 10, 2022	BUY	$131.98 - $163.75 $1.65 Million - $2.05 Million	12,513 Added 5.75%	230,229 $37.3 Million
Q4 2021 Jan 26, 2022	SELL	$107.43 - $135.93 $1.61 Million - $2.04 Million	-15,023 Reduced 6.45%	217,716 $29.5 Million
Q3 2021 Nov 03, 2021	BUY	$106.4 - $120.78 $6.29 Million - $7.14 Million	59,097 Added 34.03%	232,739 $25.1 Million
Q2 2021 Aug 10, 2021	SELL	$105.21 - $117.21 $22.1 Million - $24.6 Million	-210,029 Reduced 54.74%	173,642 $19.6 Million
Q1 2021 May 13, 2021	BUY	$102.3 - $112.62 $811,239 - $893,076	7,930 Added 2.11%	383,671 $41.5 Million
Q4 2020 Feb 09, 2021	BUY	$80.49 - $108.67 $15 Million - $20.2 Million	186,084 Added 98.12%	375,741 $40.3 Million
Q3 2020 Nov 12, 2020	SELL	$85.91 - $100.83 $506,869 - $594,897	-5,900 Reduced 3.02%	189,657 $16.6 Million
Q2 2020 Aug 10, 2020	BUY	$73.37 - $98.18 $1.09 Million - $1.45 Million	14,813 Added 8.2%	195,557 $19.2 Million
Q1 2020 May 12, 2020	SELL	$64.5 - $97.79 $1.17 Million - $1.77 Million	-18,110 Reduced 9.11%	180,744 $13.8 Million
Q4 2019 Feb 13, 2020	BUY	$72.13 - $90.25 $2.03 Million - $2.54 Million	28,163 Added 16.5%	198,854 $17.6 Million
Q3 2019 Nov 08, 2019	SELL	$62.98 - $75.72 $218,288 - $262,445	-3,466 Reduced 1.99%	170,691 $12.9 Million
Q2 2019 Aug 07, 2019	SELL	$65.7 - $83.98 $269,698 - $344,737	-4,105 Reduced 2.3%	174,157 $12.7 Million
Q1 2019 May 13, 2019	SELL	$77.14 - $90.79 $292,206 - $343,912	-3,788 Reduced 2.08%	178,262 $14.4 Million
Q4 2018 Feb 12, 2019	SELL	$77.85 - $96.01 $19,851 - $24,482	-255 Reduced 0.14%	182,050 $16.8 Million
Q3 2018 Nov 13, 2018	BUY	$88.91 - $98.84 $694,031 - $771,545	7,806 Added 4.47%	182,305 $17.2 Million
Q2 2018 Aug 13, 2018	BUY	$89.78 - $106.23 $5.87 Million - $6.94 Million	65,367 Added 59.9%	174,499 $16.2 Million
Q1 2018 May 11, 2018	SELL	$92.01 - $123.21 $3.1 Million - $4.15 Million	-33,650 Reduced 23.57%	109,132 $10.3 Million
Q4 2017 Feb 12, 2018	SELL	$89.56 - $98.21 $3.25 Million - $3.56 Million	-36,237 Reduced 20.24%	142,782 $13.8 Million
Q3 2017 Nov 09, 2017	SELL	$69.85 - $89.22 $1.49 Million - $1.9 Million	-21,263 Reduced 10.62%	179,019 $15.9 Million
Q2 2017 Aug 11, 2017	BUY	N/A	200,282	200,282 $14.5 Million

Others Institutions Holding ABBV

# of Institutions

3,651

Shares Held

1.24B

Call Options Held

15.5M

Put Options Held

11.6M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $303B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

News

Stay updated on Van Eck Associates Corp with notifications on news.

Account

Van Eck Associates Corp Abb Vie Inc. Transaction History